Identifying Gut Microbiome Mediated Mechanisms for Diastolic Dysfunction Improvement After Bariatric Surgery
确定肠道微生物介导的减肥手术后改善舒张功能障碍的机制
基本信息
- 批准号:10442822
- 负责人:
- 金额:$ 44.66万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-06-01 至 2027-05-31
- 项目状态:未结题
- 来源:
- 关键词:AffectAgonistAnatomyAnimal ModelAnti-Inflammatory AgentsAntioxidantsBacteriaBile AcidsBody Weight decreasedCaloric RestrictionCardiacCardiac MyocytesCardiovascular systemCell LineDataDevelopmentDiseaseEFRACEngineeringFailureFecesFunctional disorderGastrectomyGene ExpressionGoalsHeartHeart failureHumanImpairmentIn VitroInflammationInterventionKnockout MiceLeadMeasuresMediatingMedicalMetabolicMetabolic stressMetagenomicsMicrobial GeneticsMolecularMorbidity - disease rateMusMuscle CellsNuclearObese MiceObesityOperative Surgical ProceduresPhysiologicalPlasmaPluripotent Stem CellsPostoperative PeriodReceptor ActivationReceptor GeneReceptor SignalingRecoveryRodentSequence AnalysisSignal TransductionTechniquesTestingTreatment FailureVentricularbariatric surgerybeta diversitydietary restrictiondietingfunctional improvementgastrointestinalgut microbesgut microbiomegut microbiotaheart functionimprovedin vivomicrobialmortalitymouse modelnovelobese patientsobesity treatmentpreservationreceptorreceptor expression
项目摘要
Project Summary
Sleeve gastrectomy (SG), is a type of bariatric surgery, which improves obesity-related diastolic dysfunction, a
hallmark finding of heart failure with preserved ejection fraction (HFpEF). As weight reduction through dieting
and caloric restriction fails to improve cardiac function, this suggests a mechanism for diastolic function
improvement initiated from the alteration in gastrointestinal anatomy after SG. The broad, long-term objective
of this project is to explore if gut microbial changes after SG, lead to a bile acid pool rich in farnesoid X receptor
(FXR) agonists, that mediate diastolic function improvements. In Specific Aim 1, we will test the hypothesis that
the post-SG gut microbiome increases plasma bile acid FXR agonists as a mechanism for cardiac function
improvement. Studies will be conducted utilizing fecal material transfer of SG mice as well as metagenomic
sequence analysis of SG stool from rodents and humans to determine the transferable effect of the gut
microbiome on the plasma BA pool and diastolic function. In Specific Aim 2, we will determine whether SG
plasma decreases cardiomyocyte metabolic stress via FXR activation. Human and rodent cardiomyocyte cell
lines will be engineered for regulated FXR expression to determine whether SG plasma reduces cardiac
metabolic stress through FXR agonism. In Specific Aim 3, we will determine whether SG improves diastolic
function through cardiomyocyte FXR signaling in vivo by performing surgery and assessing cardiac function in a
cardiomyocyte-specific FXR knockout mouse model. We hypothesize that SG enhances FXR signaling through
microbial-derived products to improve cardiac function. These findings will enhance our understanding of the
mechanisms for diastolic recovery after bariatric surgery to develop novel surgical and non-surgical therapies for
diastolic dysfunction and HFpEF which replicate the metabolic mechanisms generated by a SG.
项目摘要
袖状胃切除术(SG)是一种减肥手术,可改善肥胖相关的舒张功能障碍,
射血分数保留性心力衰竭(HFpEF)的标志性发现。通过节食减肥
限制热量摄入不能改善心脏功能,这表明舒张功能的机制
改善始于SG后胃肠道解剖结构的改变。广泛的长期目标
本项目的目的是探索SG后肠道微生物的变化,是否导致富含法尼醇X受体的胆汁酸池
(FXR)激动剂,介导舒张功能改善。在具体目标1中,我们将检验以下假设:
SG后肠道微生物组增加血浆胆汁酸FXR激动剂作为心脏功能的机制
改进.将利用SG小鼠的粪便物质转移以及宏基因组进行研究
啮齿动物和人类SG粪便的序列分析,以确定肠道的可转移效应
微生物组对血浆BA池和舒张功能的影响。在具体目标2中,我们将确定SG是否
血浆通过FXR活化降低心肌细胞代谢应激。人和啮齿动物心肌细胞
细胞系将被工程化以调节FXR表达,以确定SG血浆是否降低心脏功能。
代谢应激通过FXR激动。在特定目标3中,我们将确定SG是否改善舒张压
通过进行手术和评估心脏功能,
心肌细胞特异性FXR敲除小鼠模型。我们假设SG通过增强FXR信号传导,
微生物衍生产品,以改善心脏功能。这些发现将加深我们对
减肥手术后舒张期恢复的机制,以开发新的手术和非手术疗法,
舒张功能障碍和HFpEF,其复制了SG产生的代谢机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Tammy Lyn Kindel其他文献
Correction: SAGES guidelines for the management of comorbidities relevant to metabolic and bariatric surgery
- DOI:
10.1007/s00464-025-11537-3 - 发表时间:
2025-01-13 - 期刊:
- 影响因子:2.700
- 作者:
Sunjay S. Kumar;Claire Wunker;Amelia Collings;Varun Bansal;Theofano Zoumpou;Julietta Chang;Noe Rodriguez;Andrew Sabour;Lisa Renee Hilton;Omar M. Ghanem;Bradley S. Kushner;Lindsey Jean Loss;Essa M. Aleassa;Ivy N. Haskins;Subhashini Ayloo;Adam Reid;David Wayne Overby;Peter Hallowell;Tammy Lyn Kindel;Bethany J. Slater;Francesco Palazzo - 通讯作者:
Francesco Palazzo
SAGES guidelines for the management of comorbidities relevant to metabolic and bariatric surgery
- DOI:
10.1007/s00464-024-11433-2 - 发表时间:
2024-12-11 - 期刊:
- 影响因子:2.700
- 作者:
Sunjay S. Kumar;Claire Wunker;Amelia Collings;Varun Bansal;Theofano Zoumpou;Julietta Chang;Noe Rodriguez;Andrew Sabour;Lisa Renee Hilton;Omar M. Ghanem;Bradley S. Kushner;Lindsey Jean Loss;Essa M. Aleassa;Ivy N. Haskins;Subhashini Ayloo;Adam Reid;David Wayne Overby;Peter Hallowell;Tammy Lyn Kindel;Bethany J. Slater;Francesco Palazzo - 通讯作者:
Francesco Palazzo
Bariatric surgery and relevant comorbidities: a systematic review and meta-analysis
- DOI:
10.1007/s00464-025-11528-4 - 发表时间:
2025-02-07 - 期刊:
- 影响因子:2.700
- 作者:
Claire Wunker;Sunjay Kumar;Peter Hallowell;Amelia Collings;Lindsey Loss;Varun Bansal;Bradley Kushner;Theofano Zoumpou;Tammy Lyn Kindel;D. Wayne Overby;Julietta Chang;Subhashini Ayloo;Andrew F. Sabour;Omar M. Ghanem;Essa Aleassa;Adam Reid;Noe Rodriguez;Ivy N. Haskins;L. Renee Hilton;Bethany J. Slater;Francesco Palazzo - 通讯作者:
Francesco Palazzo
Tammy Lyn Kindel的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Tammy Lyn Kindel', 18)}}的其他基金
Identifying Gut Microbiome Mediated Mechanisms for Diastolic Dysfunction Improvement After Bariatric Surgery
确定肠道微生物介导的减肥手术后改善舒张功能障碍的机制
- 批准号:
10626829 - 财政年份:2022
- 资助金额:
$ 44.66万 - 项目类别:
The role of GLP-1 in cardiac recovery after bariatric surgery in obesity-induced heart failure
GLP-1 在肥胖引起的心力衰竭减肥手术后心脏恢复中的作用
- 批准号:
10320340 - 财政年份:2019
- 资助金额:
$ 44.66万 - 项目类别:
The role of GLP-1 in cardiac recovery after bariatric surgery in obesity-induced heart failure
GLP-1 在肥胖引起的心力衰竭减肥手术后心脏恢复中的作用
- 批准号:
10080367 - 财政年份:2019
- 资助金额:
$ 44.66万 - 项目类别:
Is GIP Involved in the Resolution of Diabetes After Roux-en-y Gastric Bypass?
GIP 是否参与 Roux-en-y 胃绕道手术后糖尿病的缓解?
- 批准号:
7545584 - 财政年份:2008
- 资助金额:
$ 44.66万 - 项目类别:
Is GIP Involved in the Resolution of Diabetes After Roux-en-y Gastric Bypass?
GIP 是否参与 Roux-en-y 胃绕道手术后糖尿病的缓解?
- 批准号:
7677438 - 财政年份:2008
- 资助金额:
$ 44.66万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 44.66万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 44.66万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 44.66万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 44.66万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 44.66万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 44.66万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 44.66万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 44.66万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 44.66万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 44.66万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




